154566-08-2Relevant academic research and scientific papers
ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme
Gribble, Andrew D.,Dolle, Roland E.,Shaw, Antony,McNair, David,Novelli, Riccardo,Novelli, Christine E.,Slingsby, Brian P.,Shah, Virendra P.,Tew, David,Saxty, Barbara A.,Allen, Mark,Groot, Pieter H.,Pearce, Nigel,Yates, John
, p. 3569 - 3584 (2007/10/03)
ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of 2-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme. The best compounds, 58, 68, 71, 74 have reversible K(i)'s in the 1-3 μM range against the isolated rat enzyme. As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP- citrate lyase.
Phenylderivate as inhibitors of ATP citrate lyase
-
, (2008/06/13)
Compounds of the formula STR1 where the substituents are defined in the specification useful in the treatment of hyperlipidemia.
